Advertisement


Wasat Mansoor, MBChB, PhD, on Esophageal Cancer: Quality of Life With Pembrolizumab and Chemotherapy

2021 Gastrointestinal Cancers Symposium

Advertisement

Wasat Mansoor, MBChB, PhD, of The Christie NHS Foundation Trust, discusses phase III results from the KEYNOTE-590 trial, which showed no deterioration in health-related quality of life when pembrolizumab was added to chemotherapy in patients with metastatic and unresectable esophageal cancers (Abstract 168).



Related Videos

Pancreatic Cancer

Matthew H.G. Katz, MD, on Pancreatic Cancer: Preoperative mFOLFIRINOX for Resectable Disease

Matthew H.G. Katz, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the Alliance A021501 study, which showed that administering mFOLFIRINOX before surgery was associated with a favorable overall survival rate relative to historical data in patients with borderline resectable adenocarcinoma of the pancreas (Abstract 377).

Pancreatic Cancer

Talia Golan, MD, on Pancreatic Cancer: Olaparib for BRCA-Mutated Disease

Talia Golan, MD, of the Oncology Institute, Sheba Medical Center, discusses phase III results from the POLO trial, which explored the question of whether maintenance olaparib could improve overall and progression-free survival for patients with germline BRCA-mutated metastatic pancreatic cancer (Abstract 378).

Neuroendocrine Tumors

Rocio Garcia-Carbonero, MD, on Treating Neuroendocrine Tumors of Nonpancreatic Origin With Octreotide Acetate and Axitinib

Rocio Garcia-Carbonero, MD, of Hospital Universitario 12 De Octubre, discusses results of the phase II/III AXINET trial, which showed that axitinib plus long-acting release octreotide improved overall response compared with placebo and octreotide in patients with advanced grade 1 or 2 extrapancreatic neuroendocrine tumors. However, no significant improvement in progression-free survival was observed (Abstract 360).

Colorectal Cancer

Romain Cohen, MD, PhD, on Colon Cancer: Prognostic Value of Tumor Deposits

Romain Cohen, MD, PhD, of the Mayo Clinic and Sorbonne University, discusses a post-hoc analysis of phase III results from the CALGB/SWOG 80702 study, which showed that adding the number of tumor deposits, a negative prognostic factor, to the count of lymph node metastases may improve the accuracy of TNM staging (Abstract 10).

Hepatobiliary Cancer

Andrew X. Zhu, MD, PhD, on IDH1-Mutant Cholangiocarcinoma: Ivosidenib vs Placebo

Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses final results from the phase III ClarIDHy study, which showed that ivosidenib may improve overall and progression-free survival compared with placebo in patients with previously treated cholangiocarcinoma and an isocitrate dehydrogenase 1 mutation (Abstract 266).

Advertisement

Advertisement



Advertisement